Loading...
Given the relatively high prevalence of HIV drug resistance among treatment-naive individuals, the U.S. Department of Health and Human Services recommends pretreatment genotypic resistance testing for all HIV-infected patients, including pregnant women. One of the most recent analyses supporting this recommendation involved pregnant women who enrolled in the Women and Infants Transmission Study between June 1998 and December 2004.
In this analysis, researchers examined the prevalence of resistance to 3TC and nelfinavir, two medications that have frequently been used to prevent vertical transmission of HIV. Women were eligible for analysis if they exhibited detectable viral loads (≥500 copies/mL) and were treatment-naive or had initiated trea…